Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2021 | $3.50 → $3.75 | Buy | Roth Capital |
4 - CHARLES & COLVARD LTD (0001015155) (Issuer)
4 - CHARLES & COLVARD LTD (0001015155) (Issuer)
4 - CHARLES & COLVARD LTD (0001015155) (Issuer)
Gainers Color Star Tech (NASDAQ:ADD) shares increased by 18.9% to $0.28 during Tuesday's regular session. The market value of their outstanding shares is at $6.3 million. Lixiang Education Hldg (NASDAQ:LXEH) shares increased by 17.13% to $0.37. The company's market cap stands at $4.3 million. Golden Sun Health (NASDAQ:GSUN) stock increased by 12.51% to $8.0. The market value of their outstanding shares is at $15.2 million. Dogness (Intl) (NASDAQ:DOGZ) stock increased by 9.08% to $15.01. The company's market cap stands at $191.0 million. Charles & Colvard (NASDAQ:CTHR) stock moved upwards by 7.2% to $2.31. The company's market cap stands at $6.9 million. Losers Jiade (NASDAQ:JDZG) sha
SC 13D/A - CHARLES & COLVARD LTD (0001015155) (Subject)
SC 13G/A - CHARLES & COLVARD LTD (0001015155) (Subject)
SC 13D/A - CHARLES & COLVARD LTD (0001015155) (Subject)
Conference Call with Accompanying Slide Presentation Scheduled Today at 4:30 PM ET RESEARCH TRIANGLE PARK, N.C., May 2, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, reported financial results for the third quarter ended March 31, 2024 ("Third Quarter Fiscal 2024"). Management Commentary "We remain committed to growth despite a challenging third quarter. We believe our strategic initiatives, continued investments in innovative technology, and dedica
RESEARCH TRIANGLE PARK, N.C., April 23, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, will host an investor conference call and webcast presentation to discuss its financial results for the third quarter ended March 31, 2024 ("Third Quarter Fiscal Year 2024") at 4:30 p.m. ET on Thursday, May 2, 2024. The Company will release its financial results after market close on the same day. Third Quarter Fiscal Year 2024 Conference Call DetailsDate and Time: T
Conference Call with Accompanying Slide Presentation Scheduled Today at 4:30 PM ET RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, reported financial results for the second quarter ended December 31, 2023 ("Second Quarter Fiscal 2024"). Management Commentary "We acknowledge the recent industry shift has presented us with numerous challenges and has significantly impacted our earnings. However, we do not believe t
ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti
RESEARCH TRIANGLE PARK, N.C., June 28, 2021 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab created moissanite and lab grown diamonds, announced today the Company's addition to the Russell Microcap® Index, effective after the US market opens on June 28, 2021, as a part of the Russell indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines
Roth Capital reiterated coverage of Charles & Colvard with a rating of Buy and set a new price target of $3.75 from $3.50 previously
8-K - CHARLES & COLVARD LTD (0001015155) (Filer)
NT 10-Q - CHARLES & COLVARD LTD (0001015155) (Filer)
8-K - CHARLES & COLVARD LTD (0001015155) (Filer)
4 - CHARLES & COLVARD LTD (0001015155) (Issuer)
4 - CHARLES & COLVARD LTD (0001015155) (Issuer)
4 - CHARLES & COLVARD LTD (0001015155) (Issuer)
ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company") (NASDAQ:CTHR) today announced that on October 18, 2024, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of all required periodic reports (the "Listing Rule"), as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "Form 10-K"), with the Securities and Exchange Commission (the "SEC"). The Form 10-K was due on September 30, 2024. The Com
Notes that Purported Nomination of Director Candidates by a Riverstyx Principal Is Invalid and that the Nominations Will Not be Recognized RESEARCH TRIANGLE PARK, N.C., Oct. 7, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company") (NASDAQ:CTHR) today commented on a letter sent to the Company's shareholders and released publicly by Riverstyx Capital Management, LLC ("Riverstyx"). The Company provided the following statement in response: On August 27, Charles & Colvard received a purported notice (the "Notice") from Ben Franklin, a principal of Riv